Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate - LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids. It lowers blood ammonia by stimulating the urea cycle and glutamine synthesis in the liver and skeletal muscle. Available as oral granules, oral solution, and IV infusion.
## Primary Indications
- Adjunctive treatment of hepatic encephalopathy (HE) in patients with cirrhosis or acute liver failure
- Reduction of elevated blood ammonia levels
## Adult Dosing
- **Oral:** 3–6 g three times daily (9–18 g/day total). Granules dissolved in water or juice.
- **IV infusion:** 20–40 g/day, typically given as 20 g in 500 mL IV fluid over 4–6 hours. Maximum infusion rate: 5 g/hour.
- Duration: Usually 7–14 days for acute HE; longer for chronic HE per clinical response.
## Pediatric Dosing
- **Limited data; not FDA-approved for children.** Dosing is based on small studies and expert opinion.
- **Oral:** 0.15–0.3 g/kg/day divided into 2–3 doses. Maximum: 18 g/day.
- **IV:** 0.15–0.3 g/kg/day as continuous or divided infusions. Maximum infusion rate: 5 g/hour.
- Use only under specialist guidance.
## Dose Adjustments
- **Renal impairment:** Caution in severe renal failure (CrCl <30 mL/min) due to risk of amino acid accumulation. Reduce dose or avoid.
- **Hepatic impairment:** No specific adjustment; titrate to ammonia levels and clinical response.
## Contraindications
- Hypersensitivity to L-ornithine, L-aspartate, or any excipient
- Severe renal failure (CrCl <30 mL/min) unless benefit outweighs risk
- Severe metabolic acidosis
## Adverse Effects
- **Common:** Nausea, vomiting, diarrhea, abdominal pain (especially with oral form)
- **IV:** Injection site reactions, phlebitis, headache, dizziness
- **Rare:** Hyperammonemia (paradoxical), electrolyte disturbances (especially with high doses)
## Key Drug Interactions
- **Lactulose:** Additive effect in lowering ammonia; may reduce lactulose dose requirement
- **Rifaximin:** Synergistic effect in HE; monitor for over-response
- **Diuretics:** Risk of hypokalemia/hypomagnesemia; monitor electrolytes
- **Potassium-sparing diuretics:** Theoretical risk of hyperkalemia (aspartate component)
## Monitoring
- **Ammonia levels:** Baseline and periodically (target: <50–80 µmol/L depending on lab)
- **Hepatic encephalopathy grade:** Clinical assessment (West Haven criteria)
- **Renal function:** Serum creatinine, BUN at baseline and regularly
- **Electrolytes:** Especially potassium, magnesium, phosphate
- **Liver function tests:** ALT, AST, bilirubin, INR
## Clinical Pearls
- LOLA is **not a first-line agent** for HE; lactulose and rifaximin are standard. Use as add-on when ammonia remains elevated.
- IV LOLA may be more effective than oral in acute HE due to better bioavailability.
- Onset of action: Oral 2–4 hours; IV 30–60 minutes.
- Can be mixed with common IV fluids (NS, D5W, Ringer's lactate). Do not mix with alkaline solutions.
- Taste of oral granules is unpleasant; mix with sweetened juice or yogurt.
- **Not approved by FDA** for HE; widely used in Europe, Asia, and Latin America. Check local formulary.
---
*This information is for educational purposes only. Always verify current prescribing information, local protocols, and product labeling before initiating therapy. Dosing and indications may vary by country and regulatory status.*
